DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for fallopian tube cancer — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFallopian tube cancer maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fallopian tube cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
poly(ADP-ribose) polymerase family member 3 (PARP3) — PARP3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-oxo-3,4-dihydroquinazolin-2-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4GV2 · 1.8 Å · ligand 3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-[(1R)-1-(pyridin-2-yl)ethyl]propanamide (5ME). Experimental structure, not a prediction.
What the evidence adds up to
Twenty-two patients with primary carcinoma of the fallopian tube treated at the Royal Marsden Hospital had an overall 5-year survival of 48%. The place of radiotherapy and chemotherapy in management remained unestablished in that 1981 report.
A 1994 study treated 14 patients, most with advanced disease, using cisplatin, adriamycin, and cyclophosphamide (CAP) in 10 patients or carboplatin plus cyclophosphamide in 4 patients. Eleven patients had clinically measurable disease; 8 had a complete clinical response, 2 had a partial response, and 1 had progressive disease. Of the 8 complete responders, 5 underwent second-look operation, and pathological complete response was confirmed in 4. The median survival was 40 months, and the actuarial 5-year survival rate was 48%. Three patients relapsed after 14, 16, and 20 months from completion of chemotherapy and died despite second-line treatment. The authors concluded the carcinoma is very responsive to cisplatin-containing regimens.
A 2024 case report describes a young teenage girl with recurrent fallopian tube carcinoma who responded well to surgery and chemotherapy. The report notes the disease is rare, frequently occurs among post-menopausal women, and is often grouped under epithelial ovarian cancer.
What is still missing: prospective trials large enough to define optimal primary therapy for this rare disease; reliable stratification by stage and residual disease; and any evidence that the high response rates to platinum-based regimens translate into durable cures for most patients, given the relapses and deaths observed even among pathological complete responders.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BJOG An International Journal of Obstetrics & Gynaecology · 1981 · 54 citations
PRIMARY CARCINOMA OF THE FALLOPIAN TUBE
AbstractTwenty-two patients with primary carcinoma of the Fallopian tube treated at the Royal Marsden Hospital are reported. The age distribution, parity and variety of presentation of the disease were in accordance with previous reports in the literature. Overall survival at 5 years was 48% and the place of radiotherapy and chemotherapy in its management remains to be established.
American Journal of Clinical Oncology · 1994 · 31 citations
Treatment of Primary Fallopian Tube Carcinoma with Cisplatin-Containing Chemotherapy
AbstractBecause of the rarity of the primary fallopian tube carcinoma, optimal primary therapy is still not well defined, and there is little information available regarding the efficacy of combination chemotherapy in advanced disease. The experience obtained by treating 14 patients with fallopian tube carcinoma--most of them with advanced disease--using a combination of cisplatin, adriamycin, and cyclophosphamide (CAP) (10 patients) or carboplatin plus cyclophosphamide (4 patients) is reported. One patient had Stage Ic disease, 2 had Stage II, 9 had Stage III, and 2 had Stage IV. Eleven patients had clinically measurable disease (> 2 cm) at the start of chemotherapy. Eight of these patients had a complete clinical response (CR), 2 had partial response (PR), and 1 had progressive disease (PD). Of the 8 CR patients, 5 underwent second-look operation (SLO). Pathological complete response (pCR) confirmed in 4 out of 5 patients at SLO. The 3 patients without measurable disease (< 2 cm) after primary surgery had an indeterminate response to chemotherapy. Two of them (Stages Ic and II, respectively) had a negative SLO, while the third patient with Stage IV disease, who refused the SLO, remains disease-free 41+ months. This high response rate shows that this carcinoma is very responsive to cisplatin- or cisplatin analogue-containing regimens. One pCR and two clinical CR patients relapsed after 20, 14, and 16 months, respectively, from the completion of chemotherapy and died despite the second-line treatment. The toxicity of the regimens was moderate. The median survival was 40 months, and the actuarial 5-year survival rate was 48%. Carcinoma of the fallopian tube appears to respond favorably to cisplatin- or carboplatin-containing chemotherapy.
Borneo Journal of Medical Sciences (BJMS) · 2024 · 0 citations · open access
A Young Girl with Recurrent Fallopian Tube Carcinoma (FTC): An Interesting Case Report
AbstractPrimary fallopian tube carcinoma (FTC) is a rare disease which frequently occurs among post-menopausal women. It is often grouped under the epithelial ovarian cancer umbrella. The treatment of choice is surgery and chemotherapy. Our patient was a young teenage girl with recurrent FTC who responded well to surgery and chemotherapy. We discuss on the epidemiology, risk factors, principles of management and prognosis of FTC.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
